These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18249144)

  • 1. Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists.
    Wang T; Duan Y
    J Mol Graph Model; 2008 Jun; 26(8):1287-95. PubMed ID: 18249144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV co-receptor CCR5: structure and interactions with inhibitors.
    Wang T; Duan Y
    Infect Disord Drug Targets; 2009 Jun; 9(3):279-88. PubMed ID: 19519482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
    Billick E; Seibert C; Pugach P; Ketas T; Trkola A; Endres MJ; Murgolo NJ; Coates E; Reyes GR; Baroudy BM; Sakmar TP; Moore JP; Kuhmann SE
    J Virol; 2004 Apr; 78(8):4134-44. PubMed ID: 15047829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.
    Lau G; Labrecque J; Metz M; Vaz R; Fricker SP
    J Biol Chem; 2015 Apr; 290(17):11041-51. PubMed ID: 25767113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
    Tsamis F; Gavrilov S; Kajumo F; Seibert C; Kuhmann S; Ketas T; Trkola A; Palani A; Clader JW; Tagat JR; McCombie S; Baroudy B; Moore JP; Sakmar TP; Dragic T
    J Virol; 2003 May; 77(9):5201-8. PubMed ID: 12692222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
    Moonsamy S; Dash RC; Soliman ME
    Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
    Gadhe CG; Kothandan G; Cho SJ
    J Biomol Struct Dyn; 2013; 31(11):1251-76. PubMed ID: 23153179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and molecular interactions of CCR5 inhibitors with CCR5.
    Maeda K; Das D; Ogata-Aoki H; Nakata H; Miyakawa T; Tojo Y; Norman R; Takaoka Y; Ding J; Arnold GF; Arnold E; Mitsuya H
    J Biol Chem; 2006 May; 281(18):12688-98. PubMed ID: 16476734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.
    Paterlini MG
    Biophys J; 2002 Dec; 83(6):3012-31. PubMed ID: 12496074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
    Seibert C; Ying W; Gavrilov S; Tsamis F; Kuhmann SE; Palani A; Tagat JR; Clader JW; McCombie SW; Baroudy BM; Smith SO; Dragic T; Moore JP; Sakmar TP
    Virology; 2006 May; 349(1):41-54. PubMed ID: 16494916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.
    Li G; Haney KM; Kellogg GE; Zhang Y
    J Chem Inf Model; 2009 Jan; 49(1):120-32. PubMed ID: 19166361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.
    Mirza MU; Saadabadi A; Vanmeert M; Salo-Ahen OMH; Abdullah I; Claes S; De Jonghe S; Schols D; Ahmad S; Froeyen M
    Eur J Pharm Sci; 2020 Dec; 155():105537. PubMed ID: 32890663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
    Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.